PHARMACOTHERAPY OF SOCIAL PHOBIA

社交恐惧症是一种高度流行的，致残的，慢性焦虑症 与大量职业、社会和学术相关的疾病 成人和儿童的损伤。 这会增加 抑郁症、药物滥用和经济依赖。然而，尽管如此， 社交恐惧症受到的关注比其他焦虑症少， 目前还没有普遍接受的治疗方法。 然而，具体的心理社会和精神药理学治疗， 证明了功效。认知行为团体治疗（CBGT）， 由Heimberg开发，已被证明上级对照疗法， 由Liebowitz首先研究的MAOI苯乙肼已被证明上级 安慰剂在几个对照试验。在一部小说中， 合作已成为该领域的典范，Heimberg和 Liebowitz一起比较了苯乙肼，CBGT，药丸安慰剂和一种 可靠的心理社会控制治疗，并发现苯乙肼和CBGT 在多种测量方面具有上级优势，并具有明显的临床获益。 苯乙肼起效更快，与CBGT一起对一些 措施，而CBGT往往是更持久的治疗后， 中止 虽然苯乙肼和CBGT产生了积极的影响，一些 患者，尤其是广泛性社交恐惧症患者， 足够了苯乙肼后也有明显的复发 中止因此，仍然需要治疗 社交恐惧症比这两种更有效更持久 如通常给予的治疗。具体来说， MAOI和CBGT从未被评估过。由于各种原因， 联合治疗可能比单独治疗更有效 治疗，比单独用药更持久，特别是对 广泛性社交恐惧症患者如果是，则苯乙肼/CBGT组合 治疗对于许多临床上 目前的需求没有得到很好的满足。 为了满足这些需求，Liebowitz和Heimberg现在将比较CBGT， 苯乙肼，这两种治疗的组合，和安慰剂药片， 一项关于社交恐惧症治疗的研究。结果评价标准为 盲法独立评估员访谈、自我报告问卷，以及 标准化行为测试亚型和治疗的贡献 此外，亦会研究地点至结果。这项研究将大大 提高我们对社交恐惧症有效治疗方法的认识。

Social Phobia is a highly prevalent, disabling, and chronic anxiety disorder associated with substantial vocational, social, and academic impairment in adults as well as children. It increases the risk of depression, substance abuse and financial dependence. Nevertheless, social phobia has received less attention than other anxiety disorders, and there are no universally accepted treatments for this condition. However, specific psychosocial and psychopharmacological treatments have demonstrated efficacy. Cognitive Behavioral Group Therapy (CBGT), developed by Heimberg, has proven superior to control therapies, while the MAOI phenelzine, first studies by Liebowitz, has proven superior to placebo in several controlled trials. In a novel and highly successful collaboration that has become a model in the field, Heimberg and Liebowitz together compared phenelzine, CBGT, pill placebo, and a credible psychosocial control treatment, and found phenelzine and CBGT superior on a variety of measures and of distinct clinical benefits. Phenelzine was faster acting and more effective with CBGT on some measures, while CBGT tended to be more durable following treatment discontinuation. While phenelzine and CBGT produced positive effects, a number of patients, especially among generalized social phobics, did not respond sufficiently. There was also significant relapse following phenelzine discontinuation. Therefore, there is still a need for treatments for social phobia that are more effective and more durable that those two treatments as typically administered. Specifically the combination of an MAOI and CBGT has never been evaluated. For a variety of reasons, the combination treatment may be more effective that either individual therapy, more durable than medication alone, and especially effective for patients with generalized social phobia. If so, combined phenelzine/CBGT treatment would be of distinct benefit for many patients whose clinical needs are currently not well met. To address these needs, Liebowitz and Heimberg will now compare CBGT, phenelzine, the combination of these two treatments, and pill placebo in a acute study the treatment of social phobia. Outcome is evaluated by blind independent assessor interviews, self-report questionnaires, and standardized behavioral tests. The contributions of subtype and treatment site to outcome will also be examined. This study should substantially enhance our knowledge of effective treatments for social phobia.